-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $45

Benzinga·03/03/2026 16:40:35
Listen to the news
HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.